DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS: ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND ITS COMPONENTS

被引：0

作者：

Kavanaugh, A. ^{[1
]}

Coates, L. ^{[2
]}

Merola, J. F. ^{[3
]}

Mease, P. J. ^{[4
,5
]}

Nowak, M. ^{[6
]}

Banerjee, S. ^{[7
]}

Hippeli, L. ^{[8
]}

Lehman, T. ^{[9
]}

机构：

[1] Univ Calif San Diego, Rheumatol, La Jolla, CA 92093 USA

[2] Univ Oxford, Orthopaed Rheumatol & Musculoskeletal Sci, Oxford, England

[3] Harvard Med Sch, Brigham & Womens Hosp, Dermatol, Boston, MA 02115 USA

[4] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA

[5] Univ Washington, Rheumatol Res, Seattle, WA 98195 USA

[6] Bristol Myers Squibb, Clin R&D, Princeton, NJ USA

[7] Bristol Myers Squibb, Rheumatol & Dermatol, Princeton, NJ USA

[8] Bristol Myers Squibb, Biostats, Princeton, NJ USA

[9] Bristol Myers Squibb, WW Med Immunol, Princeton, NJ USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷

关键词：

D O I：

10.1136/annrheumdis-2022-eular.1849

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

POS1039

引用

页码：835 / 835

页数：1

共 50 条

[41] Assessment of Direct and Indirect Impact on Pain and Fatigue Outcomes in a Phase 2 Clinical Trial of Deucravacitinib, a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Active PsA: A Mediation Analysis
Mease, Philip J.
Eder, Lihi
Ogdie, Alexis R.
Deodhar, Atul
Banerjee, Subhashis
Jou, Ying-Ming
Nowak, Miroslawa
Lehman, Thomas
Strand, Vibeke
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 994 - 996
[42] Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial
Zhang, Jianzhong
Ding, Yangfeng
Wang, Ping
Li, Linfeng
Pan, Weili
Lu, Yan
Cheng, Hao
Jiang, Xian
Ho, Ji-Chen
Guo, Shuping
Liu, Leona
Chatterjee, Arkendu
Kisa, Renata M.
Banerjee, Subhashis
BRITISH JOURNAL OF DERMATOLOGY, 2025, 192 (03) : 402 - 409
[43] DESIGN OF A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIAL OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
Werth, V. P.
Merola, J. F.
Wenzel, J.
Delev, N.
Kothari, H.
Meier, R.
Singhal, S.
Madireddi, M.
Korish, S.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1506 - 1506
[44] Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial
Mease, Philip
Helliwell, Philip S.
Silwinska-Stanczyk, Paula
Miakisz, Malgorzata
Ostor, Andrew
Peeva, Elena
Vincent, Michael
Sikirica, Vanja
Winnette, Randall
Qiu, Ruolun
Li, Gang
Feng, Gang
Beebe, Jean
Martin, David
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1009 - 1011
[45] Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Scalp, Nail, and Palmoplantar Psoriasis in Japanese Patients With Plaque Psoriasis: Subset Analysis of the Phase 3 POETYK PSO-4 Trial
Imafuku, Shinichi
Okubo, Yukari
Tada, Yayoi
Ohtsuki, Mamitaro
Shao, Yanqiu
Colston, Elizabeth
Kisa, Renata M.
Banerjee, Subhashis
Morita, Akimichi
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB147 - AB147
[46] Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Gooderham, Melinda
Spelman, Lynda
Imafuku, Shinichi
Romanelli, Marco
Merola, Joseph F.
Armstrong, April W.
Colston, Elizabeth
Banerjee, Subhashis
Scharnitz, Thomas
Blauvelt, Andrew
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB35 - AB35
[47] Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Achievement of Absolute PASI Thresholds in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Thaci, Diamant
Lebwohl, Mark
Gooderham, Melinda
Warren, Richard B.
Foley, Peter
Gottlieb, Alice B.
Banerjee, Subhashis
Hippeli, Lauren
Kisa, Renata
Griffiths, Christopher
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 119 - 120
[48] Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: Achievement of absolute PASI thresholds in the phase 3 POETYK PSO-1 and PSO-2 trials
Lebwohl, Mark
Gooderham, Melinda
Warren, Richard B.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB41 - AB41
[49] Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 2-year Efficacy by Prior Biologic Treatment in the Phase 3 POETYK PSO Program
Warren, Richard B.
Armstrong, April W.
Imafuku, Shinichi
Paul, Carle
Kircik, Leon
Colston, Elizabeth
Scharnitz, Thomas
Wang, Tao
Banerjee, Subhashis
Strober, Bruce
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB147 - AB147
[50] BMS-986165, an oral selective tyrosine kinase 2 inhibitor: Evaluation of changes in laboratory parameters in response to treatment in a phase 2 trial in psoriasis
Gordon, Kenneth
Papp, Kim Alexander
Gooderham, Melinda
Morita, Akimichi
Foley, Peter
Thaci, Diamant
Ren, Haobo
Wei, Lan
Banerjee, Subhashis
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB140 - AB140

← 1 2 3 4 5 →